Communications Medicine (Jan 2023)

Remdesivir improves biomarkers associated with disease severity in COVID-19 patients treated in an outpatient setting

  • David Z. Pan,
  • Pamela M. Odorizzi,
  • Andre Schoenichen,
  • Mazin Abdelghany,
  • Shuguang Chen,
  • Anu Osinusi,
  • Scott D. Patterson,
  • Bryan Downie,
  • Kavita Juneja,
  • Jeffrey J. Wallin

DOI
https://doi.org/10.1038/s43856-022-00232-2
Journal volume & issue
Vol. 3, no. 1
pp. 1 – 6

Abstract

Read online

Pan et al. determine the impact of the antiviral remdesivir (RDV) on biomarkers associated with clinical outcomes, within a randomized, double-blind, placebo-controlled phase 3 study (PINETREE). They demonstrate that RDV-treated patients have an accelerated reduction in soluble angiopoietin-2, D-dimer and neutrophil-to-lymphocyte ratios.